AWM
ITCI

Able Wealth Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Able Wealth Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9
Closed -$645 – 600
2023
Q4 		$645 Buy
+9
New +$518 ﹤0.01% 545

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Able Wealth Management's ITCI Position: Q1 2024 in Review

Able Wealth Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 9 shares — an estimated $645 sold.

Able Wealth Management first reported a position in ITCI in Q4 2023 and held it in 1 quarter. The position peaked at $645 in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Able Wealth Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • Able Wealth Management sold 9 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $645.
  • Able Wealth Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 1 quarter.
  • Able Wealth Management's Intra-Cellular Therapies Inc. position peaked at $645 in Q4 2023.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Able Wealth Management's 13F filing for Q1 2024, filed 1 Nov 2024.